KRAZATI

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, Lithuania.

Active ingredients

The drug KRAZATI contains one active pharmaceutical ingredient (API):

1	Adagrasib UNII 8EOO6HQF8Y - ADAGRASIB
	Adagrasib is a selective, irreversible inhibitor of KRAS (Kirsten rat sarcoma viral oncogene homolog) G12C that covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in its inactive, GDP-bound conformation, which prevents KRAS-dependent downstream signalling. Adagrasib inhibits tumour cell growth and viability in cells harbouring KRAS G12C mutations and results in regression in KRAS G12C-positive nonclinical tumour models with minimal off-target activity.
	Read more about Adagrasib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
KRAZATI Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XX77		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX77

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3059120, 3059131
LT	Valstybinė vaistų kontrolės tarnyba	1098629, 1098630
US	FDA, National Drug Code	80739-812